This recent transaction increases Todd Brady’s holding in the company by 1.76% to a total of $3.33 million. Following Todd Brady’s last ALDX Buy transaction on February 21, 2017, the stock climbed by 0.7%.
The company has a one-year high of $16.70 and a one-year low of $4.31. Currently, Aldeyra Therapeutics has an average volume of 379.37K.
Starting in September 2018, ALDX received 31 Buy ratings in a row. Six different firms, including Canaccord Genuity and Cantor Fitzgerald, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes.